| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_63b7ef6f9fc54fb35f1b8e12a69e3ecd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3e4804e7b400237945930b36389ea713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d7cea8e7d22abdc3b5ccb3f8d13340c4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5b8c54ea90db08a7c219d02951a51027 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3511
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-15 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
| filingDate |
1995-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c310d669acf5b25eb0874ec0e4b1c211
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e2a33db5ee1aa2aa9c0256d4a072dfef
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9a083d4f7bd5cf3a5d678e31ad5397d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a0d10c4910fa164b42f7baa195a15694 |
| publicationDate |
1996-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2197117-A1 |
| titleOfInvention |
Antisense and triplex therapeutic agents and methods |
| abstract |
Antisense and anti-gene oligonucleotides and modified oligonucleotides with plural intercalating molecules attached for use in antisense and triplex therapy. Virally infected blood, blood plasma or serum samples are rendered significantly less infectious while maintaining the integrity of the sample for clinical analysis. Synthetic strands of oligonucleotides, and/or nucleaseresistant derivatives of oligonucleotides having intercalating agent molecules attached thereto provide an additive for incorporation into a blood sample which is to undergo analytical tests and procedures. Sterilization of a significant number of intracellular target viruses in the sample renders the sample significantly less capable of infecting those handling it. An appropriate binding material additive, such as an antibody or aptamer, which is specific for epitopes or other binding sites on the free or extracellular target virus, may also be used, either alone or in combination with the intracellular strand ingredients. |
| priorityDate |
1994-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |